Business Context and Reporting Period
This Form 6-K filing by Galapagos NV (not Lakefront Biotherapeutics NV) covers the month of April 2025. The document reports the results of the Annual Shareholders' Meeting and Extraordinary Shareholders' Meeting held on April 29, 2025. The meeting addressed governance matters, including the approval of financial accounts for the year ended December 31, 2024, and board appointments.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. It confirms that shareholders approved the non-consolidated annual accounts for the financial year ended December 31, 2024, but the numerical details of these accounts are not included in this report.
Material Changes and Governance Actions
- Board Appointment: Shareholders confirmed the appointment of Mr. Oleg Nodelman as a non-executive director, effective October 7, 2024, following the resignation of Mr. Daniel Baker. His mandate is for four years and will not be remunerated.
- Auditor Mandate Extension: The statutory auditor, BDO Bedrijfsrevisoren BV, was appointed to provide assurance on sustainability reporting under the Corporate Sustainability Reporting Directive (CSRD) for the financial year ending December 31, 2025.
- Auditor Remuneration: The remuneration for the sustainability reporting assurance for the 2025 financial year was set at EUR 80,000.00 (VAT exclusive).
- Approvals: Shareholders approved the remuneration report and granted release from liability to current and former Board members and the statutory auditor for the 2024 financial year.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on operational outlook, or specific risk factors. The primary focus is on the ratification of past financial results and the formalization of governance structures required by Belgian law and the CSRD.
Key Facts for Investor Verification
- Verify the full non-consolidated annual accounts for the year ended December 31, 2024, which were approved but not detailed in this filing.
- Confirm the impact of the new non-executive director, Mr. Oleg Nodelman, on board composition and strategy.
- Review the Company's sustainability reporting for 2024 and 2025 to understand the scope of the new CSRD assurance mandate.
- Check the Company's website (glpg.com) for the full minutes and documentation of the April 29, 2025, meeting.